Aria Pharmaceuticals

Aria Pharmaceuticals

Growth Stage




Funding data not publicly available


Start Date


Close Date


Min. Goal
Max. Goal
Min. Investment


Security Type

Convertible Note

SEC Filing Type

RegD 506(c)

Valuation Cap




Year Founded



Healthcare & Pharmaceuticals

Tech Sector



Palo Alto, California

Aria Pharmaceuticals, with a valuation of $85 million, is raising funds on OurCrowd through Reg D 506(c) raise. The company has developed an AI-driven drug delivery platform for therapeutic development candidates. The software platform helps in identifying promising hits, derisking the opportunities through preclinical studies, and progressing drug candidates to clinical trials. Aria Pharmaceuticals has already modeled over 300 diseases and has identified 1,000 diseases that it could address. Andrew A. Radin founded Aria Pharmaceuticals in 2014. The current crowdfunding campaign has a minimum target of $10,000 and a maximum target of $2,510,000. The campaign proceeds will be used for growth and expansion.
Create a free account today to gain access to KingsCrowd analytics.

Funding data not publicly available

Upgrade to gain access

Pay Monthly
Annually (Save 17%)


$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.
Add to portfolio
Aria Pharmaceuticals on OurCrowd 2021
Platform: OurCrowd
Security Type: Convertible Note
Valuation: $85,000,000

Follow company

Follow Aria Pharmaceuticals on OurCrowd 2021

Buy Aria Pharmaceuticals's Deal Report

Warning: according to the close date for this deal, Aria Pharmaceuticals may no longer be accepting investments.

Aria Pharmaceuticals Deal Report

Get KingsCrowd’s comprehensive report on Aria Pharmaceuticals including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether Aria Pharmaceuticals is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the Aria Pharmaceuticals deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge